CP03 | Cell Death Assesment Unit
CP03 Services
The “Cell Death Assessment Unit” provides expertise and application-oriented assessment of different types of RCD both in situ within the affected tissues but also in vitro in cultured cells. This unit can support the SFB Groups in the evaluation of different types of cell death and thereby ensure standardization across the SFB groups.
Equipment Platform
The Cell Death Assessment Unit provides access to different equipment. For further information please see the table below. CP03 can assist with the use of the equipment and provide information on protocols and analysis of specific experiments.
| Equipment | Specificities | Information |
| IncuCyte® | IncuCyte® Cell-by-Cell Analysis Software Module | IncuCyte internal |
| PAM Chlorophyll Fluorescence Imager | M-Series MAXI-Version (SystemI) | PAM internal |
Histology Platform
The SFB would like to support their groups with the Histology platform of CP03. Within CP03 we can provide different services.
Basic service: Tissue embedding & sectioning, H&E stainings.
Protocols & Antibodies: Working protocols for Cell Death stainings in specific stainings
Establishment of stainings: Adapting and establishment of stainings for specific needs
Protocols for standardized experimental methodologies that identify dying and dead cells and the responsible RCD pathways in culture and in tissues can be found here or at this sciebo folder (you can get the password from the SFB1403 office).
Stainings for Necroptosis (p-MLKL, p-Ripk3, P-Ripk1) are currently being established, we can not provide running protocols yet.
Prof. Dr. Hamid Kashkar
Institute for Molecular Immunology, TRIO
Contact: h.kashkar(at)uni-koeln(dot)de
For more information visit: Kashkar lab
Prof. Dr. Silvia von Karstedt
Department of Translational Genomics, CECAD
Contact: s.vonkarstedt(at)uni-koeln(dot)de
For more information visit: von Karstedt Lab
Project related Publications
2007 - 2019
Haubert D, Gharib N, Rivero F, Wiegmann K, Hösel M, Krönke M, and Kashkar H. (2007). PtdIns(4,5)P-restricted plasma membrane localization of FAN is involved in TNF-induced actin reorganization. EMBO J., 26, 3308–3321.
Herz J, Pardo J, Kashkar H, Schramm M, Kuzmenkina E, Bos E, Wiegmann K, Wallich R, Peters PJ, Herzig S, Schmelzer E, Krönke M, Simon MM, and Utermöhlen O. (2009). Acid sphingomyelinase is a critical regulator of cytotoxic granule secretion by primary T Lymphocytes. Nat. Immunol. 10, 761-8.
Böcke A, Sieger D, Kashkar H, and Krönke M (2012). FAN mediates navigational capacity of macrophages responding to wounds and infection- live imaging studies in zebrafish larvae. J Immunol. 189, 1559-66
Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann PN, Schüll S, Andree M, Coutelle O, Yazdanpanah B, Seeger JM, Klubertz D, Drebber U, Hacker UT, Krönke M, Mauch C, Hoppe T, and Kashkar H. (2013).Ubiquitin C-Terminal Hydrolase-L1 Potentiates Cancer Chemosensitivity by Stabilizing NOXA. Cell Rep. 3, 881-91.
Coutelle O, Hornig-Do HT, Witt A, Andree M, Schiffmann LM, Liwschitz M, Seeger JM, Piekarek M, Brinkmann K, Hallek M, Krönke M, Trifunovic A, Eming SA, Wiesner RJ, Hacker UT, and Kashkar H. (2014) Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing. EMBO Mol. Med. 6, 624-639
Andree, M., Seeger, J.M., Schull, S., Coutelle, O., Wagner-Stippich, D., Wiegmann, K., Wunderlich, C.M., Brinkmann, K., Broxtermann, P., Witt, A., Fritsch, M., Martinelli, P., Bielig, H., Lamkemeyer, T., Rugarli, E.I., Kaufmann, T., Sterner-Koch, A., Wunderlich, F.T., Villunger, A., Martins, L.M., Krönke, M., Kufer, T.A., Utermöhlen, O., and Kashkar, H. (2014). BID-dependent release of mitochondrial SMAC dampens XIAP-mediated immunity against Shigella. EMBO J 33, 2171-2187.
Hartwig, T.*, Montinaro, A.*, von Karstedt, S.*, Sevko, A., Surinova, S., Chakravarthy, A., Taraborrelli, L., Draber, P., Lafont, E., Arce Vargas, F., et al. (2017). The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Mol. Cell 65, 730–742.e5. *These authors contributed equally to this work.
von Karstedt, S.*, Montinaro, A.*, and Walczak, H. (2017). Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat. Rev. Cancer 17, 352–366. *These authors contributed equally to this work.
von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A.D., Taraborrelli, L., et al. (2015). Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 27, 561–573.
Lemke, J., von Karstedt, S., Abd El Hay, M., Conti, A., Arce, F., Montinaro, A., Papenfuss, K., El-Bahrawy, M. A., and Walczak, H. (2014). Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 21, 491-502.